Роль ВИЧ-инфекции в развитии факторов риска сердечно-сосудистых заболеваний у лиц с естественным течением ВИЧ-инфекции и получающих антиретровирусную терапию
Роль ВИЧ-инфекции в развитии факторов риска сердечно-сосудистых заболеваний у лиц с естественным течением ВИЧ-инфекции и получающих антиретровирусную терапию
Роль ВИЧ-инфекции в развитии факторов риска сердечно-сосудистых заболеваний у лиц с естественным течением ВИЧ-инфекции и получающих антиретровирусную терапию
Сердечно-сосудистые заболевания (ССЗ) являются одной из основных причин смерти в современном мире. Особое значение в профилактике их развития придается концепции факторов риска (ФР). Помимо ФР в настоящее время выделяют так называемые особые группы населения, в которых необходимо проведение более агрессивных профилактичеcких мероприятий в связи с высокой вероятностью развития ССЗ. Одну из таких групп составляют ВИЧ-инфицированные пациенты. Известно, что среди них выше распространенность как традиционных, так и «новых» ФР. В то же время, несмотря на большое количество проведенных исследований, мало данных о ФР ССЗ у ВИЧ-инфицированных пациентов с сохранной функцией иммунной системы с естественным течением ВИЧ-инфекции, а также получающих антиретровирусную терапию. Целью проведенного нами исследования явилась оценка степени выраженности традиционных и «новых» ФР у ВИЧ-инфицированных пациентов с сохранной функцией иммунной системы c естественным течением ВИЧ-инфекции и получающих антиретровирусную терапию.
Cardiovascular diseases are one of the main reasons of death in the modern world. Risk factor conception is emphasized in theirs prophylaxis. Nowadays besides risk factors mark out so called «special» population groups in which prophylactic actions school be more aggressive because of high cardiovascular risk. One of such groups is HIV-infected patients. It well known that among them the prevalence of traditional and «new» risk factors is much higher. At the same time in spite of the fact that there are a lot of trials it is lack of evidence about cardiovascular risk factors in HIV-infected patients with the saved immune system function as in «naïve», so in antiretroviral treated patients. The aim of our investigation was to evaluate range of express traditional and «new» risk factors in «naïve» and antiretroviral treated HIV-infected patients with the saved immune system function.
1. Мировой отчет по неинфекционным заболеваниям. ВОЗ. Женева, 2010.
2. Obel N, Thomsen HF, Kronborg G et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007; 44: 1625–31.
3. Triant VA. HIV and Cardiovascular Disease. HIV/AIDS Annual Update, 2010.
4. Savès M, Chêne G, Ducimetière P et al. French WHO MONICA Project and the APROCO (ANRS EP11) Study Group. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37: 292–8.
5. El-Sadr WM, Mullin CM, Carr A et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med 2005; 6 (2): 114–21.
6. Iffen TS, Efobi H, Usoro CAO et al. Lipid Profile of HIV-Positive Patients Attending University of Calabar Teaching Hospital, Calabar – Nigeria. World J Med Sci 2010; 5 (4): 89–93.
7. Oko F, Naito T, Oike M et al. Correlation between HIV disease and lipid metabolism in antiretroviral – naïve HIV – infected patients in Japan. J Infect Chemotherapy 2012; 18 (1): 17–21.
8. Grunfeld C, Kotler DP, Hamadeh R et al. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86: 27–31.
9. Daniyam CA, Iroezindu MO. Lipid Profile of Anti-Retroviral Treatment-Naive HIV-Infected Patients in Jos, Nigeria. Ann Med Health Sci Res 2013; 3 (1): 26–30.
10. Noor MA, Lo JC, Mulligan K et al. Metabolic effects of indinavir in healthy HIV-seronegative men. Aids 2001; 15: 11–8.
11. Mildvan D, Machado SG, Wilets I et al. Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. Lancet 1992; 339: 453–6.
12.Mulligan K, Grunfeld C, Tai VW et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23: 35–43.
13. Sullivan AK, Feher MD, Nelson MR et al. Marked hypertriglyceridaemia associated with ritonavir therapy. AIDS 1998; 12: 1393–4.
14. Segerer S, Bogner JR, Walli R et al. Hyperlipidemia under treatment with proteinase inhibitors. Infection 1999; 27: 77–81.
15. Periard D, Telenti A, Sudre P et al. Atherogenic dyslipidemia in HIVinfected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100: 700–5.
16. Bitnun A, Sochett E, Dick PT. Insulin Sensitivity and b-Cell Function in Protease Inhibitor-Treated and Naive Human Immunodeficiency Virus-Infected Children. JCEM 2005; 90 (1): 168–74.
17. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275: 20251–4.
18. Meininger G, Hadigan C, Rietschel P et al. Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men. Am J Clin Nutr 2002; 76: 460–5.
19. Hadigan C, Miller K, Corcoran C et al. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999; 84: 1932–7.
20. El-Sadr WM, Mullin CM, Carr A et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med 2005; 6 (2): 114–21.
21. Baker J, Ayenew W, Quick H et al. High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis 2010; 201: 285–92.
22. Jong E, Louw S, Meijers JC et al. The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy. AIDS Patient Care STDS 2009; 23: 1001–7.
23. Arildsen H, Sørensen KE, Ingerslev JM et al. Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy. HIV Med 2013; 14 (1): 1–9.
24. Bernardino J, Merino J, Serrano L et al. Longitudinal comparison of inflammatory, coagulation and metabolic biomarkers in patients who start ART versus patients who remain ART-naïve. Abstracts of the Eleventh International Congress on Drug Therapy in HIV Infection. J Int AIDS Soc 2012; 15 (4): 182–4.
25. Ledwaba L, Tavel AJ, Paul Khabo P et al. Pre-ART Levels of Inflammation and Coagulation Markers Are Strong Predictors of Death in a South African Cohort with Advanced HIV Disease PLoS One 2012; 7 (3): e24243.
26. Abdollahi A, Shoar TS. Hyperhomocysteinemia in HIV-Infected Individuals: Correlation of a Frequent Prothrombotic Factor with CD4+ Cell Count. Oman Med J 2012; 27 (3): 224–7.
27. Melenko SR, Sorokhan VD. Von Willebrand factor as a marker of endothelium disfunction on patints with HIV/AIDS. Материалы IV международной научно-практической конференции «Образование и наука». София: Бял ГРАД-БГ, 2010; 16: 56–9.
28. Miller TL, Borkowsky W, DiMeglio LA et al. Metabolic Abnormalities and Viral Replication is Associated with Biomarkers of Vascular Dysfunction in HIV-Infected Children. HIV Med 2012; 13 (5): 264–75.
29. Dolan SE, Hadigan C, Killilea KM et al. Increased Cardiovascular Disease Risk Indices in HIV-Infected Women. J Acquir Immune Defic Syndr 2005; 39: 44–54.
30. Arildsen H, Sørensen KE, Ingerslev JM et al. Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy. HIV Med 2013; 14 (1): 1–9.
31. Calmy A, Gayet-Ageron A, Montecucco F. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. 2009; AIDS 23 (8): 929–39.
32. Phillips AN, Carr A, Neuhaus J еt al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008; 13: 177–87.
33. Fisac C, Fumero E, Crespo M et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005; 19: 917–25.
34. Lane BR, Markovitz DM, Woodford NL et al. TNF-alpha inhibits HIV-1 replication in peripheral blood monocytes and alveolar macrophages by inducing the production of RANTES and decreasing C-C chemokine receptor 5 (CCR5) expression. J Immunol 1999; 163 (7): 3653–61.
35. Jeong SJ, Chin BS, Chae YT et al. Serum retinol-binding protein-4 levels are increased in HIV-infected subjects with metabolic syndrome receiving highly active antiretroviral therapy. Yonsei Med J 2012; 53 (6): 1211–5.
1 Кафедра поликлинической терапии №2 лечебного факультета ГБОУ ВПО РНИМУ им. Н.И.Пирогова, Москва;
2 ФБУН Центральный научно-исследовательский институт эпидемиологии, Москва
*irka.komarova@gmail.com
1 Pirogov Russian National Research Medical University, Department of Outpatient Therapy №2 of Medical Faculty, Moscow;
2 Central Research Institute of Epidemiology, Moscow
*irka.komarova@gmail.com